Compare · HCXY vs PEY
HCXY vs PEY
Side-by-side comparison of Hercules Capital, Inc. (HCXY) and Invesco High Yield Equity Dividend Achievers ETF (PEY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HCXY and PEY operate in n/a (n/a), so they compete in similar markets.
- HCXY carries a market cap of $4.51B.
- Over the past year, HCXY is down 0.5% and PEY is up 13.8% - PEY leads by 14.3 points.
- PEY has more recent analyst coverage (2 ratings vs 0 for HCXY).
Invesco High Yield Equity Dividend Achievers ETF
The investment seeks to track the investment results (before fees and expenses) of the NASDAQ US Dividend AchieversTM 50 Index (the "underlying index"). The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq, Inc. includes common stocks in the underlying index that have a consistent record of dividend increases, principally on the basis of dividend yield and consistent growth in dividends.
Latest HCXY
- Hercules Capital Announces Date of 2026 Annual Meeting of Stockholders
- Hercules Capital Reports First Quarter 2026 Financial Results
- Hercules Capital Enters Next Phase of Growth with Expanded Leadership Team
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the First Quarter 2026
- Hercules Capital Announces Date for Release of First Quarter 2026 Financial Results and Conference Call
- Hercules Capital Sets New Record with All-Time High New Debt and Equity Commitments
- Hercules Capital Receives a BBB (high) Affirmed Investment Grade Corporate and Credit Rating from Morningstar DBRS
- Hercules Capital Named 2025 Americas BDC Manager of the Year by Private Debt Investor
- Hercules Capital Reports Fourth Quarter and Full-Year 2025 Financial Results
- Hercules Capital Closes Institutional Notes Offering of $300.0 Million 5.350% Unsecured Notes due 2029
Latest PEY
- Walgreens Expands Specialty Pharmacy Business To Include Gene and Cell Services: Details
- Earnings Scheduled For May 11, 2022
- Earnings Scheduled For March 9, 2022
- RBC Capital reiterated coverage on Peyto Exploration & Dev with a new price target
- Peyto Exploration & Dev upgraded by TD Securities with a new price target